PT - JOURNAL ARTICLE AU - Farina Karim AU - Inbal Gazy AU - Sandile Cele AU - Yenzekile Zungu AU - Robert Krause AU - Mallory Bernstein AU - Yashica Ganga AU - Hylton Rodel AU - Ntombifuthi Mthabela AU - Matilda Mazibuko AU - Khadija Khan AU - Daniel Muema AU - Dirhona Ramjit AU - Thumbi Ndung’u AU - Willem Hanekom AU - Bernadett I. Gosnell AU - COMMIT-KZN Team AU - Richard Lessells AU - Emily Wong AU - Tulio de Oliveira AU - Mahomed-Yunus S. Moosa AU - Gila Lustig AU - Alasdair Leslie AU - Henrik Kløverpris AU - Alex Sigal TI - HIV status alters disease severity and immune cell responses in <em>β</em> variant SARS-CoV-2 infection wave AID - 10.1101/2020.11.23.20236828 DP - 2021 Jan 01 TA - medRxiv PG - 2020.11.23.20236828 4099 - http://medrxiv.org/content/early/2021/09/05/2020.11.23.20236828.short 4100 - http://medrxiv.org/content/early/2021/09/05/2020.11.23.20236828.full AB - There are conflicting reports on the effects of HIV on COVID-19. Here we analyzed disease severity and immune cell changes during and after SARS-CoV-2 infection in 236 participants from South Africa, of which 39% were people living with HIV (PLWH), during the first and second (β dominated) infection waves. The second wave had more PLWH requiring supplemental oxygen relative to HIV negative participants. Higher disease severity was associated with low CD4 T cell counts and higher neutrophil to lymphocyte ratios (NLR). Yet, CD4 counts recovered and NLR stabilized after SARS-CoV-2 clearance in wave 2 infected PLWH, arguing for an interaction between SARS-CoV-2 and HIV infection leading to low CD4 and high NLR. The first infection wave, where severity in HIV negative and PLWH was similar, still showed some HIV modulation of SARS-CoV-2 immune responses. Therefore, HIV infection can synergize with the SARS-CoV-2 variant to change COVID-19 outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Bill and Melinda Gates Investment INV-018944 to Alex Sigal. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the University of KwaZulu-Natal Institutional Review Board (approval BREC/00001275/2020). Written informed consent was obtained for all enrolled participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll de-identified data is included or available upon request.